Table 1.
Gene engineered subunit vaccine candidates and their effectiveness.
| Gene (Protein) name | Vaccine type | Challenge | Specific antibodies | Neutralizing antibodies | T cell response | Clinical outcome (n = protected animals/ total animals) | Reference |
|---|---|---|---|---|---|---|---|
| A151R, B119L, B602L, EP402RΔPRR, B438R, K205R-A104R | Adenovirus | /a | Yb | / | Y | / | (Lokhandwala et al., 2017) |
| CP204L (p32), E183L (p54), CP530R (pp62), B646L (p72), | Adenovirus | / | Y | / | Y | / | (Lokhandwala et al., 2016) |
| B646L (p72), E183L (p54), O61R (p12), EP402R (CD2v) | Vaccinia virus | / | Y | / | Partial | / | (Lopera-Madrid et al., 2017) |
| A151R, B119L, B602L, EP402RΔPRR, B438L, K205R, A104R, CP530R (pp62), B646L (p72) | Adenovirus | Y | Y | / | Y | No protection | (Lokhandwala et al., 2019) |
| EP153R, K78R (p10), CP530R (p15), CP80R, I329L, H108R, K196R, CP312R, F334L, NP419L, NP868R, B66L, H339R, R298L, K145R, B385R, F165R, F778R, S273R, MGF100-1L, A224L, MGF505-6R, B175L | Adenovirus | Y | / | / | / | No protection | (Cadenas-Fernández et al., 2020) |
| 42 replication-deficient adenovirus-Vectored multicistronic expression cassettes encoding ASFV antigens | Adenovirus | Y | Y | / | / | No protection | (Zajac et al., 2023) |
| CP2475L (p220) | Protein | / | Y | / | Y | / | (Zajac et al., 2022) |
| B646L (p72), CP204L (p30), E183L (p54), E199L, EP153R, EP364R, F317L, I329L, MGF360, MGF505 | Protein | Y | Y | / | Y | Full protection (n = 6/6); Viremia was significantly reduced | (Goatley et al., 2020) |
| CP204L (p30), E183L (p54), B646L (p72), KP177R (p22) | Protein | Y | Y | Y | / | No protection; Slight delay of clinical disease and viremia | (Neilan et al., 2004) |
| EP402R (CD2v) | Protein | Y | Y | / | / | Full protection (n = 3/3) | (Ruiz-Gonzalvo et al., 1996) |
| CP204L (p30), E183L (p54) | Protein | Y | Y | Y | / | Partial protection (n = 3/6) | (Gómez-Puertas et al., 1998) |
| CP204L (p30), E183L (p54) | Protein | Y | Y | Y | / | Full protection (n = 2/2) | (Barderas et al., 2001) |
| M448R, MGF505–7R | DNA | Y | Y | / | Y | Partial protection (n = 3/5) | (Bosch-Camós et al., 2021) |
| CP204L (p32), E183L (p54), EP402R (CD2v) | DNA | Y | Y | / | Y | Partial protection (n = 4/6) | (Argilaguet et al., 2013a) |
| ASFV DNA library | DNA | Y | Y | Y | Y | Partial protection (n = 6/10) | (Lacasta et al., 2014) |
| CP204L (p30), E183L (p54), EP402R (CD2v) | DNA | Y | Y | / | Y | Partial protection (n = 2/6); The onset time of clinical symptoms was delayed | (Argilaguet et al., 2012) |
| B646L (p72), MGF110-5L, CP204L, CP530R (pp62), I73R, I215L, A151R, C129R, E146L, L8L, M448R, MGF110-4L | DNA | Y | Y | / | Y | No protection; reduced viral load in some tissues | (Netherton et al., 2019) |
| CP204L (p32), E183L (p54), EP402R (CD2v), B646L (p72), D117L (p17), CP530R (p15, p35) | DNA–Protein | Y | Y | Nc | N | No protection; Accelerated onset of clinical symptoms, viremia, and death | (Sunwoo et al., 2019) |
a
This experiment or statistic was not performed.
b
Yes.
c
No.